A citation-based method for searching scientific literature

Sajjad Ahmad, Yasir Waheed, Saba Ismail, Muzammil Hasan Najmi, Jawad Khaliq Ansari. J Mol Liq 2021
Times Cited: 2







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.
Linlin Zhang, Daizong Lin, Xinyuanyuan Sun, Ute Curth, Christian Drosten, Lucie Sauerhering, Stephan Becker, Katharina Rox, Rolf Hilgenfeld. Science 2020
100

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
Alexandra C Walls, Young-Jun Park, M Alejandra Tortorici, Abigail Wall, Andrew T McGuire, David Veesler. Cell 2020
100

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors.
Zhenming Jin, Xiaoyu Du, Yechun Xu, Yongqiang Deng, Meiqin Liu, Yao Zhao, Bing Zhang, Xiaofeng Li, Leike Zhang, Chao Peng,[...]. Nature 2020
100

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.
Wenhao Dai, Bing Zhang, Xia-Ming Jiang, Haixia Su, Jian Li, Yao Zhao, Xiong Xie, Zhenming Jin, Jingjing Peng, Fengjiang Liu,[...]. Science 2020
488
100

Marine-Derived Pharmaceuticals - Challenges and Opportunities.
Ulrike Lindequist. Biomol Ther (Seoul) 2016
57
50

Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.
Julian Breidenbach, Carina Lemke, Thanigaimalai Pillaiyar, Laura Schäkel, Ghazl Al Hamwi, Miriam Diett, Robin Gedschold, Nina Geiger, Vittoria Lopez, Salahuddin Mirza,[...]. Angew Chem Int Ed Engl 2021
14
50


Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
Wei-Chung Chiou, Meng-Shiuan Hsu, Yun-Ti Chen, Jinn-Moon Yang, Yeou-Guang Tsay, Hsiu-Chen Huang, Cheng Huang. J Enzyme Inhib Med Chem 2021
6
50

Bacillus species; a potential source of anti-SARS-CoV-2 main protease inhibitors.
Sadia Alam, Shahida Sadiqi, Maimoona Sabir, Sobia Nisa, Sajjad Ahmad, Sumra Wajid Abbasi. J Biomol Struct Dyn 2021
3
50

Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds.
André Fischer, Manuel Sellner, Santhosh Neranjan, Martin Smieško, Markus A Lill. Int J Mol Sci 2020
70
50

SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs.
Shiv Bharadwaj, Esam Ibraheem Azhar, Mohammad Amjad Kamal, Leena Hussein Bajrai, Amit Dubey, Kanupriya Jha, Umesh Yadava, Sang Gu Kang, Vivek Dhar Dwivedi. J Biomol Struct Dyn 2020
23
50


Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Krishnaprasad Baby, Swastika Maity, Chetan H Mehta, Akhil Suresh, Usha Y Nayak, Yogendra Nayak. Arch Med Res 2021
14
50

Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.
Mohammad Z Ahmed, Qamar Zia, Anzarul Haque, Ali S Alqahtani, Omar M Almarfadi, Saeed Banawas, Mohammed S Alqahtani, Keshav L Ameta, Shafiul Haque. J Infect Public Health 2021
5
50

Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis.
Mohammed Hakmi, El Mehdi Bouricha, Ilham Kandoussi, Jaouad El Harti, Azeddine Ibrahimi. Bioinformation 2020
17
50

Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Mahmoud Kandeel, Alaa H M Abdelrahman, Kentaro Oh-Hashi, Abdelazim Ibrahim, Katharigatta N Venugopala, Mohamed A Morsy, Mahmoud A A Ibrahim. J Biomol Struct Dyn 2021
28
50

Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro.
Hongbo Liu, Fei Ye, Qi Sun, Hao Liang, Chunmei Li, Siyang Li, Roujian Lu, Baoying Huang, Wenjie Tan, Luhua Lai. J Enzyme Inhib Med Chem 2021
36
50

Crystal structure of SARS-CoV-2 papain-like protease.
Xiaopan Gao, Bo Qin, Pu Chen, Kaixiang Zhu, Pengjiao Hou, Justyna Aleksandra Wojdyla, Meitian Wang, Sheng Cui. Acta Pharm Sin B 2021
68
50

Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.
Brendan T Freitas, Ian A Durie, Jackelyn Murray, Jaron E Longo, Holden C Miller, David Crich, Robert Jeff Hogan, Ralph A Tripp, Scott D Pegan. ACS Infect Dis 2020
102
50

Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2 3CL-Protease In Vitro.
Minsu Jang, Yea-In Park, Yeo-Eun Cha, Rackhyun Park, Sim Namkoong, Jin I Lee, Junsoo Park. Evid Based Complement Alternat Med 2020
38
50

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
Fei Yu, Rong Xiang, Xiaoqian Deng, Lili Wang, Zhengsen Yu, Shijun Tian, Ruiying Liang, Yanbai Li, Tianlei Ying, Shibo Jiang. Signal Transduct Target Ther 2020
41
50

COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor.
Eduardo L Feitosa, Francisco Tiago Dos S S Júnior, José Arimatéa De O Nery Neto, Luis F L Matos, Matheus H De S Moura, Thiele Osvaldt Rosales, Guilherme Barroso L De Freitas. Int J Med Sci 2020
18
50

SARS-CoV-2 is an appropriate name for the new coronavirus.
Yuntao Wu, Wenzhe Ho, Yaowei Huang, Dong-Yan Jin, Shiyue Li, Shan-Lu Liu, Xuefeng Liu, Jianming Qiu, Yongming Sang, Qiuhong Wang,[...]. Lancet 2020
140
50

Phytochemicals of Rhus spp. as Potential Inhibitors of the SARS-CoV-2 Main Protease: Molecular Docking and Drug-Likeness Study.
Yousery E Sherif, Sami A Gabr, Nasser M Hosny, Ahmad H Alghadir, Rayan Alansari. Evid Based Complement Alternat Med 2021
1
100


Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease.
Cintia A Menéndez, Fabian Byléhn, Gustavo R Perez-Lemus, Walter Alvarado, Juan J de Pablo. Sci Adv 2020
27
50

Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants.
Muhammad Tahir Ul Qamar, Safar M Alqahtani, Mubarak A Alamri, Ling-Ling Chen. J Pharm Anal 2020
342
50


Challenges and opportunities of drug repositioning.
Natalia Novac. Trends Pharmacol Sci 2013
164
50



Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies.
Lúcio Ricardo Leite Diniz, Yunierkis Perez-Castillo, Hatem A Elshabrawy, Carlos da Silva Maia Bezerra Filho, Damião Pergentino de Sousa. Biomolecules 2021
13
50

Structure-Based Discovery of Novel Nonpeptide Inhibitors Targeting SARS-CoV-2 Mpro.
Jingyi Yang, Xiaoyuan Lin, Na Xing, Zhao Zhang, Haiwei Zhang, Haibo Wu, Weiwei Xue. J Chem Inf Model 2021
2
50

Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.
Aleix Gimeno, Júlia Mestres-Truyol, María José Ojeda-Montes, Guillem Macip, Bryan Saldivar-Espinoza, Adrià Cereto-Massagué, Gerard Pujadas, Santiago Garcia-Vallvé. Int J Mol Sci 2020
51
50

Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease.
Maya G Deshmukh, Joseph A Ippolito, Chun-Hui Zhang, Elizabeth A Stone, Raquel A Reilly, Scott J Miller, William L Jorgensen, Karen S Anderson. Structure 2021
5
50

Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation.
Adnane Aouidate, Adib Ghaleb, Samir Chtita, Mohammed Aarjane, Abdellah Ousaa, Hamid Maghat, Abdelouahid Sbai, M'barek Choukrad, Mohammed Bouachrine, Tahar Lakhlifi. J Biomol Struct Dyn 2021
13
50

Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS.
Kuo-Chen Chou, Dong-Qing Wei, Wei-Zhu Zhong. Biochem Biophys Res Commun 2003
326
50

Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads.
Kartik Mitra, Prasanth Ghanta, Sushank Acharya, Gayathri Chakrapani, Basavaraju Ramaiah, Mukesh Doble. J Biomol Struct Dyn 2021
9
50

Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor.
Manish Kumar Tripathi, Pushpendra Singh, Sujata Sharma, Tej P Singh, A S Ethayathulla, Punit Kaur. J Biomol Struct Dyn 2021
38
50

ETCM: an encyclopaedia of traditional Chinese medicine.
Hai-Yu Xu, Yan-Qiong Zhang, Zhen-Ming Liu, Tong Chen, Chuan-Yu Lv, Shi-Huan Tang, Xiao-Bo Zhang, Wei Zhang, Zhi-Yong Li, Rong-Rong Zhou,[...]. Nucleic Acids Res 2019
142
50



Exploration of natural compounds with anti-SARS-CoV-2 activity via inhibition of SARS-CoV-2 Mpro.
Shiv Bharadwaj, Amit Dubey, Umesh Yadava, Sarad Kumar Mishra, Sang Gu Kang, Vivek Dhar Dwivedi. Brief Bioinform 2021
16
50

Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (Mpro) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation.
Priyashi Rao, Arpit Shukla, Paritosh Parmar, Rakesh M Rawal, Baldev Patel, Meenu Saraf, Dweipayan Goswami. Biophys Chem 2020
26
50


2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
Katrina L Forrestall, Darcy E Burley, Meghan K Cash, Ian R Pottie, Sultan Darvesh. Chem Biol Interact 2021
5
50

Characteristics of SARS-CoV-2 and COVID-19.
Ben Hu, Hua Guo, Peng Zhou, Zheng-Li Shi. Nat Rev Microbiol 2021
639
50

Effect of mutations on binding of ligands to guanine riboswitch probed by free energy perturbation and molecular dynamics simulations.
Jianzhong Chen, Xingyu Wang, Laixue Pang, John Z H Zhang, Tong Zhu. Nucleic Acids Res 2019
52
50

Dual inhibition of COVID-19 spike glycoprotein and main protease 3CLpro by Withanone from Withania somnifera.
Vishal Shivalingappa Patil, Vrushabh B Hupparage, Ajay P Malgi, Sanjay H Deshpande, Sathgowda A Patil, Shamanand P Mallapur. Chin Herb Med 2021
4
50

In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
Zeshan Haider, Muhammad Muneeb Subhani, Muhammad Ansar Farooq, Maryum Ishaq, Maryam Khalid, Muhammad Numan Akram, Rao Sohail Ahmad Khan, Adnan Khan Niazi. Pak J Pharm Sci 2020
1
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.